Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report

References

• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–259. doi:10.4065/mcp.2010.067421364117
   PubMed Web of Science ®Google Scholar
• Tuon FF, Gortz LW, Rocha JL. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. Braz J Infect Dis. 2012;16(4):351–356. doi:10.1016/j.bjid.2012.06.00922846123
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, van Duin D. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by pseudomonas aeruginosa compared to other bacteria. Antimicrob Agents Chemother. 2017;61(6):e02671–16. doi:10.1128/AAC.02671-1628373189
   PubMed Web of Science ®Google Scholar
• Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Updat. 2019;44:100640. doi:10.1016/j.drup.2019.07.00231492517
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martínez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(11):4783–4788. doi:10.1128/AAC.00574-0919738025
   PubMed Web of Science ®Google Scholar
• Chalhoub H, Tunney M, Elborn JS, et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother. 2015;70(5):1596–1598. doi:10.1093/jac/dku55125587996
   PubMed Web of Science ®Google Scholar
• Alnimr AM, Alamri AM. Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant. J Taibah Univ Med Sci. 2020;15(3):203–210. doi:10.1016/j.jtumed.2020.04.00432647515
   PubMed Web of Science ®Google Scholar
• Mascitti H, Duran C, Nemo EM, et al. Factors associated with bacteremia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study. Antimicrob Resist Infect Control. 2018;7:116. doi:10.1186/s13756-018-0412-330288256
   PubMed Web of Science ®Google Scholar
• Tartof SY, Kuntz JL, Chen LH, et al. Development and assessment of risk scores for carbapenem and extensive β-lactam resistance among adult hospitalized patients with pseudomonas aeruginosa infection. JAMA Netw Open. 2018;1(6):e183927. doi:10.1001/jamanetworkopen.2018.392730646267
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43–48. doi:10.1128/AAC.50.1.43-48.200616377665
   PubMed Web of Science ®Google Scholar
• Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis. 1988;10(3):629–635. doi:10.1093/clinids/10.3.6293393785
   PubMedGoogle Scholar
• Zhang Y, Chen XL, Huang AW, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect. 2016;5:e27. doi:10.1038/emi.2016.2227004762
   PubMed Web of Science ®Google Scholar
• Sung JY, Koo SH, Cho HH, Kwon KC. Nosocomial infection by sequence type 357 multidrug-resistant Acinetobacter baumannii isolates in a neonatal intensive care unit in Daejeon, Korea. Ann Lab Med. 2013;33(4):279–282. doi:10.3343/alm.2013.33.4.27923826565
   PubMed Web of Science ®Google Scholar
• Zowawi HM, Syrmis MW, Kidd TJ, et al. Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region. J Med Microbiol. 2018;67(6):846–853. doi:10.1099/jmm.0.00073029664716
   PubMed Web of Science ®Google Scholar
• Mihara T, Kimura T, Momiyama K, et al. Secondary in-hospital epidemiological investigation after an outbreak of Pseudomonas aeruginosa ST357. J Infect Chemother. 2020;26(3):257–265. doi:10.1016/j.jiac.2019.09.014
   Web of Science ®Google Scholar
• Pelegrin AC, Saharman YR, Griffon A, et al. High-risk international clones of carbapenem-nonsusceptible pseudomonas aeruginosa endemic to indonesian intensive care units: impact of a multifaceted infection control intervention analyzed at the genomic level. mBio. 2019;10(6). doi:10.1128/mBio.02384-19
   Web of Science ®Google Scholar
• Taiaroa G, Samuelsen Ø, Kristensen T, Økstad OAL, Heikal A. Complete genome sequence of pseudomonas aeruginosa K34-7, a carbapenem-resistant isolate of the high-risk sequence type 233. Microbiol Resour Announc. 2018;7(4). doi:10.1128/MRA.00886-18
   Web of Science ®Google Scholar
• Witney AA, Gould KA, Pope CF, et al. Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa. Clin Microbiol Infect. 2014;20(10):O609–18. doi:10.1111/1469-0691.1252824422878
   PubMed Web of Science ®Google Scholar
• Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci. 2013;1277:91–104. doi:10.1111/j.1749-6632.2012.06796.x23163348
   PubMed Web of Science ®Google Scholar
• Turton JF, Wright L, Underwood A, et al. High-resolution analysis by whole-genome sequencing of an international lineage (Sequence Type 111) of pseudomonas aeruginosa associated with metallo-carbapenemases in the United Kingdom. J Clin Microbiol. 2015;53(8):2622–2631. doi:10.1128/JCM.00505-1526041902
   PubMed Web of Science ®Google Scholar
• Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018;73(suppl_3):iii2–iii78. doi:10.1093/jac/dky02729514274
   PubMed Web of Science ®Google Scholar
• Poirel L, Mugnier PD, Toleman MA, et al. ISCR2, another vehicle for bla(VEB) gene acquisition. Antimicrob Agents Chemother. 2009;53(11):4940–4943. doi:10.1128/AAC.00414-0919704129
   PubMed Web of Science ®Google Scholar
• Poirel L, Rotimi VO, Mokaddas EM, Karim A, Nordmann P. VEB-1-like extended-spectrum beta-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis. 2001;7(3):468–470. doi:10.3201/eid0703.01032211384532
   PubMed Web of Science ®Google Scholar
• Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45(6):568–585. doi:10.1016/j.ijantimicag.2015.03.00125857949
   PubMed Web of Science ®Google Scholar
• Sana TG, Hachani A, Bucior I, et al. The second type VI secretion system of Pseudomonas aeruginosa strain PAO1 is regulated by quorum sensing and Fur and modulates internalization in epithelial cells. J Biol Chem. 2012;287(32):27095–27105. doi:10.1074/jbc.M112.37636822665491
   PubMed Web of Science ®Google Scholar
• El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2012;40(4):1157–1163. doi:10.1097/CCM.0b013e318237790622080633
   PubMed Web of Science ®Google Scholar
• Zhang L, Hinz AJ, Nadeau JP, Mah TF. Pseudomonas aeruginosa tssC1 links type VI secretion and biofilm-specific antibiotic resistance. J Bacteriol. 2011;193(19):5510–5513. doi:10.1128/JB.00268-1121784934
   PubMed Web of Science ®Google Scholar
• Nagai H, Kubori T. Type IVB secretion systems of legionella and other gram-negative bacteria. Front Microbiol. 2011;2:136. doi:10.3389/fmicb.2011.0013621743810
   PubMed Web of Science ®Google Scholar
• Brüggemann H, Migliorini LB, Sales RO, et al. Comparative genomics of nonoutbreak pseudomonas aeruginosa strains underlines genome plasticity and geographic relatedness of the global clone ST235. Genome Biol Evol. 2018;10(7):1852–1857. doi:10.1093/gbe/evy13929982603
   PubMed Web of Science ®Google Scholar
• Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002;186(1):64–73. doi:10.1086/34106912089663
   PubMed Web of Science ®Google Scholar
• Rice SA, Tan CH, Mikkelsen PJ, et al. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J. 2009;3(3):271–282. doi:10.1038/ismej.2008.10919005496
   PubMed Web of Science ®Google Scholar
• Guzvinec M, Izdebski R, Butic I, et al. Sequence types 235, 111, and 132 predominate among multidrug-resistant pseudomonas aeruginosa clinical isolates in Croatia. Antimicrob Agents Chemother. 2014;58(10):6277–6283. doi:10.1128/AAC.03116-1425070098
   PubMed Web of Science ®Google Scholar
• Oechslin F, Piccardi P, Mancini S, et al. Synergistic interaction between phage therapy and antibiotics clears pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis. 2017;215(5):703–712. doi:10.1093/infdis/jiw63228007922
   PubMed Web of Science ®Google Scholar
• Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018;2018(1):60–66. doi:10.1093/emph/eoy00529588855
   PubMed Web of Science ®Google Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a Phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–1328. doi:10.1016/S1473-3099(18)30554-130509675
   PubMed Web of Science ®Google Scholar